Is It Really the Short-Course Radiation?

Affiliations

Comment

Ahmed Abdalla et al. Dis Colon Rectum. 2022.

. 2022 Sep 1;65(9):e919.

doi: 10.1097/DCR.0000000000002509. Epub 2022 May 25.

¹ Department of Interdisciplinary Oncology, University of South Alabama, Mobile, AL.
² Ascension St. John Hospital, Detroit, MI.

No abstract available

Comment in

Reply.
Chapman WC Jr, Parikh P, Hunt S. Chapman WC Jr, et al. Dis Colon Rectum. 2022 Sep 1;65(9):e920. doi: 10.1097/DCR.0000000000002510. Epub 2022 May 25. Dis Colon Rectum. 2022. PMID: 35671247 No abstract available.

Total Neoadjuvant Therapy With Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy.
Chapman WC Jr, Kim H, Bauer P, Makhdoom BA, Trikalinos NA, Pedersen KS, Glasgow SC, Mutch MG, Silviera ML, Roy A, Parikh PJ, Hunt SR. Chapman WC Jr, et al. Dis Colon Rectum. 2022 Feb 1;65(2):198-206. doi: 10.1097/DCR.0000000000001997. Dis Colon Rectum. 2022. PMID: 34990423

1. Chapman WC Jr, Kim H, Bauer P, et al. Total neoadjuvant therapy with short-course radiation: US experience of a neoadjuvant rectal cancer therapy. Dis Colon Rectum. 2022;65:198–206.
1. Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4:e180071.
1. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300–3307.
1. Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.
1. Conroy T, Bosset JF, Etienne PL, et al.; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–715.